Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date

Abstract

Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biologic medications approved for the treatment of plaque psoriasis include tumor necrosis factor α inhibitors, interleukin (IL)-17 or IL-17 receptor inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. Tildrakizumab-asmn is a monoclonal antibody that targets the p19 subunit of IL-23 and is approved for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This article reviews the current pharmacologic, efficacy, and safety data on tildrakizumab-asmn.

Keywords: IL-23; IL-23p19; biologics; psoriasis; tildrakizumab.

Figure 1

The mechanism of action of tildrakizumab. Notes: Tildrakizumab selectively inhibits the p19 subunit of IL-23 and neutralizes its function. Abbreviation: IL, interleukin; Th17, type 17 helper T lymphocytes; TNF-α, tumor necrosis factor alpha.